Best pharmaceutical companies in Boston, MA

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women's Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world. Pharmaceutical The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX (topiramate), approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), a biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral (risperidone), a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients, RISPERDAL CONSTA (risperidone), a long-acting injectable, and INVEGA (paliperdone) Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN (levofloxacin) and FLOXIN (ofloxacin), both in the anti-infective field; CONCERTA (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC), a treatment for chronic pain that offers a novel delivery system. Medical Devices and Diagnostics The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis' circulatory disease management products; DePuy's orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon's surgical care and women's health products; Ethicon Endo-Surgery's minimally invasive surgical products; LifeScan's blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics' professional diagnostic products and Vistakon's disposable contact lenses.

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical treatments for metabolic and cardiovascular disease, central nervous system disease, respiratory and immunology, oncology, and general medicine areas. It offers products for the treatment of type II diabetes, hypertension, insomnia, Alzheimer s-type dementia, hyperuricemia and gout, peptic ulcer, acid reflux, multiple myeloma, prostate and breast cancer, endometriosis, cancer, malignant lymphoma, and major depressive disorder diseases. The company was founded in 1998 and is based in Deerfield, Illinois. It has business and sales operations in Europe, the Russian Federation, CIS, Japan, North America, Latin America, Asia, and internationally. Takeda Pharmaceuticals U.S.A., Inc. operates as a subsidiary of Takeda Pharmaceutical Company Limited.

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases. The company is driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. Merck delivers vaccines, medications, and consumer and animal health products that can help millions around the world. Merck was founded in 1891 and is headquartered in Kenilworth, NJ.

Haemonetics specializes in blood processing technology.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

A fully integrated, life sciences commercial services company -designed to solve pricing, access, reimbursement, adherence and product delivery challenges

Covance Inc. is a global contract research organization recognized for being the world's most comprehensive drug development company. It has a team of professionals that are dedicated to advancing healthcare and delivering fast and innovative medical solutions to patients and healthcare providers. The company also offers laboratory testing services to the chemical, agrochemical, and food industries. It is also a market leader in central laboratory, toxicology, and discovery services.

A bracket is a tall punctuation mark commonly used in matched pairs within text, to set apart or interject other text. The members of the matched pair may be described as opening and closing brackets.

Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

Charles River Laboratories International, Inc. provides solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. Segments The company has two segments: Research Models and Services (RMS) and Preclinical Services (PCS), which includes Phase I clinical services. RESEARCH MODELS AND SERVICES (RMS) The company supplies research models to the drug development industry. With approximately 150 different strains the company engages in the production and sale of research models, principally genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist customers in supporting the use of research models in drug development. With multiple facilities located on three continents (North America, Europe and Asia (Japan)), the company maintains production centers, including a total of approximately 180 barrier rooms or isolator facilities located near its customers. RMS segment comprises Research Models, Research Model Services, and other related products and services

Sanofi US is part of a leading global healthcare company that discovers, develops, produces and markets innovative therapies to help protect health and enhance people's lives. Along with the other U.S. affiliates, Genzyme, Sanofi Pasteur, Merial and Chattem, they work to prevent and treat the diseases they know about today, as well as those they may face tomorrow. Sanofi US, with headquarters in Bridgewater, New Jersey, employs more than 16,900 professionals throughout the country.

Radius Health Care, Inc. provides nursing care facility. The company was founded in 1997 and is based in Southborough, Massachusetts.

PPD offers a broad range of early development services, early phase clinical trial services and nonclinical consulting, helping clients increase efficiencies and accelerate the drug development process. Their scientific expertise and experience as well as wide range of equipment and services enable them to meet clients' needs.

Dova Pharmaceuticals a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we're dedicated to bringing brilliant medicine to market.

Hotspot Therapeutics derives medical solutions from natural solutions.